home / stock / hcm / hcm news

HCM News and Press, HUTCHMED (China) Limited From 04/10/23

Stock Information
Company Name: HUTCHMED (China) Limited
Stock Symbol: HCM
Market: NASDAQ
Website: hutch-med.com
Menu
HCM HCM Quote HCM Short HCM News HCM Articles HCM Message Board
Get HCM Alerts

News, Short Squeeze, Breakout and More Instantly...
HCM - Week In Review: Suzhou Duality Out-Licenses 2 ADCs To BioNTech In $1.7 Billion Deal

2023-04-10 00:38:00 ET Summary Duality Biologics (Suzhou) out-licensed global rights (ex-China) for two ADC candidates to BioNTech in a deal worth $170 million upfront and up to $1.5 billion in milestone payments. Shanghai HutchMed has completed the rolling submission of a US NDA ...
HCM - Bullfrog, HUTCHMED top healthcare gainers; Scilex, Allarity among losers

2023-04-06 10:02:19 ET Gainers: Bullfrog AI ( BFRG ) +16% . HUTCHMED (China) ( HCM ) +10% . Aprea Therapeutics ( APRE ) +8% . Clearside Biomedical ( CLSD ) +5% . Soleno Therapeutics ( SLNO ) +5% . Losers: Scilex ( SCLX ...

HCM - Bullfrog, Butterfly top healthcare gainers; Clearmind, Pyxis among losers

2023-04-04 10:04:33 ET Gainers: Bullfrog AI ( BFRG ) +89% . Butterfly Network ( BFLY ) +26% . Mangoceuticals ( MGRX ) +14% . Encompass Health ( EHC ) +11% . HUTCHMED (China) ( HCM ) +10% . Losers: Clearmind Medicine ( CM...

HCM - Hutchmed starts registration phase for cancer trials after talks with Chinese regulator

2023-04-04 06:06:01 ET Hutchmed (China) ( NASDAQ: HCM ) said it consulted China's National Medical Products Administration (NMPA) and reached agreements to start the registration phase enrollments in ongoing trials of drugs HMPL-453 and savolitinib for gastric cancer. ...
HCM - HUTCHMED Initiates Registration Phase Enrollments of HMPL-453 for IHCC and Savolitinib for Gastric Cancer following NMPA Consultations

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 04, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has consulted the China National Medical Products Administration (“NMPA”) and reached ...

HCM - HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer

— NDA supported by data from global Phase III FRESCO-2 study in the U.S., Europe, Japan and Australia along with data from Phase III FRESCO study conducted in China — — FRESCO-2 showed fruquintinib treatment reduced the risk of death by 3...

HCM - HUTCHMED Announces Closing of Fruquintinib License to Takeda Outside China

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., March 14, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM, HKEX:13) today announces that, further to its announcement on January 23, 2023 and following the completion of customary closing ...
HCM - HUTCHMED Confirms No Assets Held at Silicon Valley Bank

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., March 13, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ” or the “Company”) (Nasdaq/AIM:​HCM, HKEX:​13) today confirms that it does not have any exposure to Silicon Valley Bank (&#x...

HCM - Fresh Tracks, LifeStance top healthcare gainers; Intelligent Bio, Miromatrix among losers

2023-03-08 10:06:57 ET Gainers: Fresh Tracks Therapeutics ( FRTX ) +42% . LifeStance Health Group ( LFST ) +24% . Assure Holdings ( IONM ) +19% . Mesoblast ( MESO ) +19% . Treace Medical Concepts ( TMCI ) +17% . Losers: ...

HCM - HUTCHMED (China) Limited (HCM) Q4 2022 Earnings Call Transcript

HUTCHMED (China) Limited (HCM) Q4 2022 Earnings Conference Call February 28, 2023, 08:00 AM ET Company Participants Mark Lee - SVP Corporate Finance and Development Weiguo Su - CEO and Chief Scientific Officer Hong Chen - Chief Commercial Officer Johnny Cheng - CFO...
Previous 10 Next 10